Introduction Acute-on-chronic liver failure (ACLF) is a highly dynamic and life-threatening syndrome marked by intense systemic inflammation and immune dysregulation. In Asia, hepatitis B virus (HBV) reactivation is a leading trigger of ACLF.
Introduction
Acute-on-chronic liver failure (ACLF) is a highly dynamic and life-threatening syndrome marked by intense systemic inflammation and immune dysregulation. In Asia, hepatitis B virus (HBV) reactivation is a leading trigger of ACLF. However, the longitudinal immune trajectories that drive progression, recovery, or deterioration in HBV-related ACLF (HBV-ACLF) remain poorly defined. This study used single-cell multiomics to map immune evolution during the disease course.
Summary
In this longitudinal analysis of 17 hospitalised patients with HBV-ACLF and 15 controls, single-cell RNA sequencing and proteomics of peripheral blood mononuclear cells revealed stage-specific immune reprogramming. Early ACLF was characterised by expansion of VCAN⁺CD14⁺ monocytes with activated interferon-stimulated genes, fuelling an inflammatory surge following HBV relapse. As the disease progressed, hyperinflammatory CXCR2⁺ neutrophils and CD163⁺ monocytes became enriched and were strongly associated with deterioration. Cytotoxic T cells were reduced and functionally exhausted in progressive disease, partly driven by immunosuppressive CXCR2⁺ neutrophils. Pharmacologic CXCR2 inhibition reduced neutrophil infiltration and restored cytotoxic T-cell function in experimental models, suggesting therapeutic potential.
Six immune cellular modules were identified for patient stratification. CM2 and CM6 predicted adverse outcomes, while CM3 marked a potential early therapeutic window. This study provides a dynamic immune atlas of HBV-ACLF and supports immune-targeted precision strategies for risk stratification and intervention.
Introduction: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary liver cancer with poor prognosis and limited treatment options. While ICC has traditionally been considered a malignancy of biliary epithelial cells, increasing evidence suggests that hepatocytes can...
Introduction: Liver fibrosis is the key determinant of long-term outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Activated hepatic stellate cells (HSCs) drive fibrogenesis, but effective antifibrotic therapies remain unavailable. This study investigated whether blocking the succinate–GPR91...
Introduction: The progression from metabolic dysfunction-associated fatty liver (MAFL) to metabolic dysfunction-associated steatohepatitis (MASH) is driven by complex interactions between hepatocytes and immune cells. This study identifies a novel spatial mechanism in the periportal (PP)...
Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the close interaction between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. This review highlights the emerging role of the gut microbiome, particularly butyrate-producing bacteria, as a central...
• Small intestinal adenocarcinoma (SIA) is a rare gastrointestinal cancer with limited disease-specific prognostic biomarkers and generally poor outcomes. • This nationwide Dutch population-based study evaluated whether three routinely available immunohistochemical markers—CK7, CK20, and CDX2—have...
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to insulin resistance and type 2 diabetes, with the liver traditionally viewed as a key regulator of blood glucose through hepatic glucose production. However, emerging...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.